FROST & SULLIVAN - DEVELOPING A CURE FOR HEPATITIS FORCES DEVELOPMENT OF NOVEL EFFECTIVE THERAPIES
MOUNTAIN VIEW, Calif., Sep 27, 1999 /PRNewswire via COMTEX/ -- With
an overwhelming majority of hepatitis patients unresponsive to current
treatments, participants in the hepatitis therapy markets are focusing
their energies on research & development innovation. Companies that
capitalize on key technology developments and bring them to market
first, will benefit from a large patient base awaiting new and
effective treatments.
"New drugs that completely eliminate viral infections and work for the
majority of patients have a very large potential in this market," says
Frost & Sullivan Pharmaceutical Industry Analyst Marina Ulmishek. "R&D
innovation is the most crucial factor in narrowing the gap between
existing therapies and non-responders."
According to new strategic research by Frost & Sullivan
(www.frost.com), U.S. Hepatitis Therapy Markets, the major industry
segments of hepatitis B and hepatitis C therapies collectively accrued
revenues of $40.4 million and $107.3 million in 1998, respectively.
There are currently no markets for hepatitis A, D, E, or G therapies,
because these afflictions are not associated with chronic illness and
these therapies are not in high demand.
U.S. Hepatitis Therapy Markets provides an overview of the key
technological developments in R&D and the benefits of an identified
patient base. Improving diagnostic procedures can increase the patient
base by identifying previously undiagnosed patients. Diagnostic
improvements have only recently made mass-testing a convenient reality
and, in the process, have paved the way for tremendous growth in the
hepatitis therapy markets.
Ulmishek adds, "A great challenge to the hepatitis therapy markets is
in identifying carriers. Future market growth will depend on
identifying and treating patients who are currently unaware that they
are carriers of the virus." With projected revenues increasing
significantly over the next five years, companies that continue to
utilize emerging diagnostic technologies will have a competitive
advantage.
From a competitive standpoint, established companies hold a distinct
advantage over new market entrants. Nevertheless, brand loyalty and
patient care are critical factors that determine market share. Frost &
Sullivan's research indicates that products which are first to market
typically maintain a large market share lead years after the
introduction of new and similar brands.
This healthcare industry research has integrated the Market Engineering
consulting philosophy into the entire research process. Critical phases
of this research included: Identification of industry challenges,
market engineering measurements, strategic recommendations, planning
and market monitoring. All of the vital elements of this system help
the market participants navigate successfully through the hepatitis
therapy markets.
Frost & Sullivan presents Market Engineering awards to companies that
have worked hard to make a positive contribution to the hepatitis
therapies industry. Recipients of these awards for U.S. Hepatitis
Therapy Markets include: Amgen for the 1998 Market Engineering Customer
Focus Award, Gilead Sciences for the 1998 Market Engineering Product
Innovation Award, and Schering-Plough for the 1998 Market Engineering
Competitive Strategy Award, 1998 Market Engineering Sales Strategy
Award, as well as the 1998 Market Engineering Marketing Strategy Award.
Companies identified by Frost & Sullivan as market participants and
related organizations within U.S. Hepatitis Therapy Markets include:
Agouron Pharmaceuticals, Inc., Amgen, Inc., Axys Pharmaceuticals, Inc.,
Biogen, Inc., Chiron Corporation, CYTOGEN Corporation, Enzo Biochem,
Genetics Institute, Inc., Gilead Sciences, Inc., Glaxo Wellcome, Inc.,
HEMISPHERx Biopharma, Inc., Hoffmann-La Roche, Inc., Hybridon, Inc.,
ICN Pharmaceuticals, Inc., Immusol Incorporated, ISIS Pharmaceuticals,
Inc., Janssen Pharmaceutica, Inc., Maxim Pharmaceuticals, Inc., Medeva
Pharmaceuticals, Protein Design Labs, Inc., Ribozyme Pharmaceuticals,
Inc., SciClone Pharmaceuticals, Inc., Schering-Plough Corporation,
Scriptgen Pharmaceuticals, Inc., SmithKline Beecham Pharmaceuticals,
Targeted Genetics Corporation, The Immune Response Corporation,
Triangle Pharmaceuticals, Inc., Trimeris, Inc., Vertex Pharmaceuticals,
Inc., Vical, Inc., Vion Pharmaceuticals, Inc., VimRx Pharmaceuticals,
Inc., XTL Biopharmaceuticals, Bayer/Pharmaceuticals Division,
Bristol-Myers Squibb Company, Cytel Corporation, Eli Lilly & Company,
Genentech, Inc., NABI, Merck & Company/ Human Health Division, American
Liver Foundation, CDC/National Center for Infectious Diseases,
Hepatitis B Foundation, Hepatitis C Foundation, Hepatitis Foundation
International, National Institute of Allergy and Infectious Diseases
Frost & Sullivan is an international marketing consulting and training
company that monitors the healthcare industry for market trends, market
measurements and strategies. This ongoing research is included as part
of the Pharmaceuticals Custom Subscription, and is used to support
industry participants with customized consulting needs. Free executive
summaries of all Frost & Sullivan research are available to the press
through our media relations department.
Visit Frost & Sullivan's Web site at frost.com .
U.S. Hepatitis Therapy Markets
Report: #5917-52 Date: September 1999 Price: $3,450
SOURCE Frost & Sullivan
(C) 1999 PR Newswire. All rights reserved.
prnewswire.com
CONTACT: Nick Mariottini of Frost & Sullivan, 650-237-4382, or fax,
650-903-0915, or nmariottini@frost.com
/Company News On-Call: prnewswire.com or fax,
800-758-5804, ext. 573125
WEB PAGE: frost.com
GEOGRAPHY: California
INDUSTRY CODE: PUB
HEA
MTC
|
